- Home
- ENTA vs GF Comparison
ENTA vs GF Comparison
Compare ENTA & GF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- GF
- Stock Information
- Founded
- ENTA 1995
- GF 1990
- Country
- ENTA United States
- GF Germany
- Employees
- ENTA N/A
- GF N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- GF Investment Managers
- Sector
- ENTA Health Care
- GF Finance
- Exchange
- ENTA Nasdaq
- GF Nasdaq
- Market Cap
- ENTA 164.6M
- GF 187.5M
- IPO Year
- ENTA 2013
- GF N/A
- Fundamental
- Price
- ENTA $11.29
- GF $11.72
- Analyst Decision
- ENTA Strong Buy
- GF
- Analyst Count
- ENTA 6
- GF 0
- Target Price
- ENTA $20.83
- GF N/A
- AVG Volume (30 Days)
- ENTA 1.5M
- GF 28.1K
- Earning Date
- ENTA 11-24-2025
- GF 01-01-0001
- Dividend Yield
- ENTA N/A
- GF 0.82%
- EPS Growth
- ENTA N/A
- GF N/A
- EPS
- ENTA N/A
- GF N/A
- Revenue
- ENTA $64,806,000.00
- GF N/A
- Revenue This Year
- ENTA $0.07
- GF N/A
- Revenue Next Year
- ENTA N/A
- GF N/A
- P/E Ratio
- ENTA N/A
- GF N/A
- Revenue Growth
- ENTA N/A
- GF N/A
- 52 Week Low
- ENTA $4.09
- GF $7.38
- 52 Week High
- ENTA $15.34
- GF $9.41
- Technical
- Relative Strength Index (RSI)
- ENTA 59.34
- GF 52.78
- Support Level
- ENTA $9.91
- GF $11.66
- Resistance Level
- ENTA $11.59
- GF $11.83
- Average True Range (ATR)
- ENTA 1.52
- GF 0.13
- MACD
- ENTA 0.19
- GF 0.03
- Stochastic Oscillator
- ENTA 52.96
- GF 69.97
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.